Bond Screener
Novo Nordisk
LEI 549300DAQ1CVT6CXN342
Organization name
Novo Nordisk A/S
Country name
Denmark
Country of registration
Denmark
Industry
Pharmaceutical Preparation and Biotechnology
Credit Ratings
in foreign currency
Public debt
16,721 mln USD
Upgrade to Premium features
Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market
Get access
-
Full access to the largest bond database
Bond parameters,
prospectuses -
Seamless
Data exportAnalyze the data in the most efficient way
-
Bond pricing
Current & historical quotes from 400+ stock exchanges & OTC market
-
Smart risk assessment
Credit ratings, financial reports
Trading Schedule Issuer map
Quotes
/
/
/
pcs.
pcs.
pcs.
- «
- 1
- ...
- {{ quotes.page - 2 }}
- {{ quotes.page - 1 }}
- {{ quotes.page }}
- {{ quotes.page + 1 }}
- {{ quotes.page + 2 }}
- ...
- {{ quotesLastPage }}
- »
Quotes provided by information providers are indicative in nature
Profile
|
Novo Nordisk is a Denmark-based company. It is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company reports two business segments: Diabetes and Biopharmaceuticals. Diabetes division offers a range of diabetes products, including modern insulins, Biopharmaceuticals division provides treatments for people with haemophilia, growth hormone deficiency and for women experiencing symptoms of menopause / 08.12
|
General information
-
Organization nameNovo Nordisk A/S
-
Organization statusOperating organization
-
Site
News
IFRS/US GAAP reports
| 2025 | |
| 2024 | |
| 2023 | |
| 2022 | |
| 2021 | |
| 2020 | |
| 2019 | |
| 2018 | |
Show all
Hide
Authorization required
You need to request access
